August 28, 2015
More than 500 researchers from academia, government, and industry gather to gain perspective on biomarker development and the application of biomarkers in preclinical and clinical research.
August 6, 2015
Testimony examined the impact of FDA-supported research in generic drugs and advocated for continued funding through renewal of the Generic Drug User Fee Amendments of 2012 (GDUFA).
February 24, 2015
Interdisciplinary group will research the effectiveness of brand versus generic iron medications used to treat anemia in kidney disease patients
January 12, 2015
Grants will support the development of quantitative pharmacometric models to advance the evaluation of generic drugs.
February 25, 2014
Researchers from academia, government, and industry discuss how increasingly large, complex datasets can be harnessed to improve the drug development process.
February 6, 2014
M-CERSI’s “America’s Got Regulatory Science Talent” judges award student first prize for new technology to combat worldwide counterfeit drug crisis.
November 6, 2013
Research seeks to improve formulation and manufacturing of opioid medications; deter individuals from abusing powerful pain relievers.
October 10, 2013
Audra Stinchcomb, PhD, will use awards to advance transdermal and topical drug delivery research.
September 13, 2013
Forum brings together FDA scientists, the University of Maryland community, and members of the public to discuss current issues in regulatory science and ongoing M-CERSI research, training, and exchange activities.
July 3, 2013
Drs. Hoag and Polli examine current regulatory science initiatives aimed at generic drugs and discuss ways in which existing initiatives can be improved.
April 3, 2013
Pharma officials from South Korea visit with the School’s faculty, eye space in University of Maryland BioPark, and help educate many of the School’s students for a week.
February 5, 2013
“America’s Got Regulatory Science Talent” judges award student first prize for his guidelines to improve reporting of adverse medication events to the Food and Drug Administration.
